Q3 2021 13F Holders as of 30 Sep 2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
90.4M
-
Number of holders
-
458
-
Total 13F shares, excl. options
-
40.4M
-
Shares change
-
-151K
-
Total reported value, excl. options
-
$4.52B
-
Value change
-
-$41.1M
-
Put/Call ratio
-
1.73
-
Number of buys
-
240
-
Number of sells
-
-189
-
Price
-
$111.93
Significant Holders of CRISPR Therapeutics AG - Common Stock (CRSP) as of Q3 2021
573 filings reported holding CRSP - CRISPR Therapeutics AG - Common Stock as of Q3 2021.
CRISPR Therapeutics AG - Common Stock (CRSP) has 458 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 40.4M shares
of 90.4M outstanding shares and own 44.68% of the company stock.
Largest 10 shareholders include ARK Investment Management LLC (7.59M shares), Capital International Investors (4.18M shares), Nikko Asset Management Americas, Inc. (3.29M shares), NEA Management Company, LLC (1.59M shares), PRICE T ROWE ASSOCIATES INC /MD/ (1.18M shares), BlackRock Inc. (1.13M shares), MACQUARIE GROUP LTD (985K shares), Bellevue Group AG (975K shares), LOOMIS SAYLES & CO L P (926K shares), and CREDIT SUISSE AG/ (913K shares).
This table shows the top 458 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.